What Femina Treats: Main Uses and Benefits

The therapeutic application of Mefenamic Acid may be part of symptomatic management across key domains involving heightened physiological responses.

Femina may offer support for symptoms related to the female cycle, being commonly used for managing painful, recurrent cramping and aches of primary dysmenorrhea and is relevant for easing symptoms associated with excessive blood loss (menorrhagia). It is also applied in contexts where short-term symptomatic support is needed for mild to moderate acute pain, such as discomfort following dental procedures, and contributes to lowering elevated body temperature (fever). Additionally, it is relevant for easing distress from joint pain and inflammation in conditions like rheumatoid arthritis and osteoarthritis.

Quick Fact: Relief for Inflammation & Episodic Pain

The symptomatic approach supports managing symptoms that interfere with daily comfort during the menstrual period and helps address symptoms that may appear suddenly and create functional strain. The medication may assist with maintaining functional stability and supports patients in coping with symptom fluctuations.

“This supportive relief helps ease the overall symptom burden during periods of increased discomfort and swelling.”

Who Can and Cannot Use Femina (Mefenamic Acid)

Official regulatory guidelines define specific patient populations permitted to use Femina and those for whom its use is strictly prohibited or restricted. This information is based on established safety and eligibility criteria.

Populations with Absolute Contraindications

Use of Mefenamic Acid is strictly prohibited in patients with certain severe pre-existing conditions:

• A known hypersensitivity to Mefenamic Acid or any other Nonsteroidal Anti-Inflammatory Drug (NSAID), including a history of NSAID-induced asthma or urticaria.
• Active gastrointestinal ulceration or chronic inflammation, or a history of GI bleeding or perforation related to prior NSAID use.
• Severe renal failure, severe hepatic failure, or severe heart failure.
• During the third trimester of pregnancy (from 30 weeks gestation) and for treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Age and Condition-Based Restrictions

Population Group	Eligibility Status	Key Restriction
Adults (( ge 18 ))	Allowed	Use is established for approved short-term indications.
Pediatric (( < 14 ) years)	Not Established	Safety and efficacy are not adequately investigated for certain indications in this age group.
Older Adults (( ge 65 ) years)	Use Restricted	Should use the lowest effective dose for the shortest possible duration due to increased risk of serious adverse reactions.
Pregnant/Lactating	Contraindicated/Not Recommended	Prohibited in the third trimester; use during breastfeeding is not recommended.
Cardiovascular Risk	Use Restricted	Caution required in patients with pre-existing cardiovascular risk factors, such as uncontrolled hypertension.

Interactions with other medicines and products

The interaction profile for Femina (Mefenamic Acid) is structured according to official government regulatory documentation detailing pharmacokinetic and pharmacodynamic relationships with other medicines and substances. Co-administration with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or COX-2 inhibitors should be avoided due to a documented additive risk of serious gastrointestinal (GI) events.

This additive pharmacodynamic risk is also noted when combined with Oral Anticoagulants, Anti-platelet Agents (including Aspirin), Corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs), all of which heighten the risk of bleeding. Furthermore, the efficacy of certain Anti-hypertensive Agents and Diuretics may be officially reduced when co-administered.

From a pharmacokinetic standpoint, the co-administration of Femina is associated with potential increases in the plasma concentrations of certain medicines. The elimination of Lithium is documented to be decreased, and levels of Methotrexate may also be increased, both leading to a risk of heightened exposure. Conversely, Magnesium Hydroxide-Containing Antacids are officially stated to significantly increase the rate and extent of Mefenamic Acid's own absorption.

Contextual restrictions include the contraindication of Mefenamic Acid for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Additionally, the risk of stomach bleeding is increased by co-administration with Alcohol (Ethanol), and smoking/tobacco is noted as an added risk factor. Regulatory documents caution that elderly patients have an increased frequency of adverse reactions related to interactions, such as serious GI bleeding.

Dual Mechanism: Inhibition of Prostaglandin Production

Mefenamic Acid acts as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2). This molecular blockade prevents the synthesis of prostaglandins from the Arachidonic Acid Cascade. This primary mechanism is complemented by a direct receptor antagonism that blocks the signaling initiated by prostaglandins already present at the cellular level.

---

Central and Peripheral Physiological Modulation

This mechanism influences both central and peripheral physiological responses. Peripherally, the drug's action dampens the excitability of sensory nerve endings, which results in reduced transmission of pain signals within the pathway. Centrally, the inhibition of PGE2 synthesis in the hypothalamus allows for the functional resetting of the body's elevated thermal set-point.

---

Mechanistic Constraints and Specificity

The mechanism is constrained by its reliance on the involvement of prostaglandins; it exhibits reduced modulation in signaling pathways where other mediators dominate. Additionally, the non-selective inhibition of the COX-1 enzyme affects the pathway responsible for basal prostaglandin activity.

How to Use Femina (Mefenamic Acid)

This section describes the administration guidelines for Mefenamic Acid (Femina).

---

Dosing and Administration

Instruction	Detail
Route of administration	Oral (swallowed by mouth) as a 250 mg capsule or tablet.
Dosing schedule	Therapy begins with an initial dose of 500 mg once, followed by a maintenance dose of 250 mg
Frequency and timing	The maintenance dose is taken every 6 hours as needed (PRN). Some guidelines specify administration up to three times daily.
Timing in relation to meals	Doses should be taken with food, milk, or a full glass of water to aid proper administration.
Course duration	Treatment for acute pain should not exceed 7 days (one week). Treatment for primary dysmenorrhea is typically limited to 2 to 3 days.

---

Use for Specific Populations

Adolescents and Older Adults

The adult dosing regimen is used for patients 14 years of age and older. For older adults (65 years and older), emphasis is placed on the general principle for NSAIDs: using the lowest effective dose for the shortest possible duration.

Missed Dose

If a scheduled dose is missed, it should be taken as soon as it is remembered. However, if the time is near that of the next scheduled dose, the missed dose is skipped, and the regular schedule is resumed. Double doses must not be taken.

Procedural Structure

Adherence to the use protocol involves initiating the regimen with the 500 mg dose, continuing with 250 mg every 6 hours as needed, and ensuring that administration occurs alongside food. These instructions define the intermittent, short-term nature of Mefenamic Acid therapy.

Research Evidence / Overview of Studies for Femina (Mefenamic Acid)

---

The Research Base for Mefenamic Acid: Overview of Study Types

The foundational clinical evidence for Femina (Mefenamic Acid) is derived primarily from decades of research, including Randomized Controlled Trials (RCTs). In these trials, participants are randomly assigned to receive Mefenamic Acid or a comparison treatment, such as a placebo. This type of research is a standard foundation for regulatory review as it provides structure for observing changes in symptoms over defined periods. To provide a broader view, Systematic Reviews and Meta-analyses also exist, which combine data from multiple individual studies. Research has explored how symptoms are measured across the various conditions where the medicine was studied.

---

Evidence for Primary Dysmenorrhea (Painful Menstruation)

Research where Mefenamic Acid was evaluated for painful menstrual cramping, or primary dysmenorrhea, primarily consists of short-term RCTs and subsequent meta-analyses. These studies included adult and adolescent women to examine patient-reported outcomes describing perceived discomfort. Researchers monitored changes in pain intensity scores and recorded the use of supplemental pain relief medication over the course of the studies.

Studies reported measurements of pain scores and supplemental analgesic use in participants, allowing comparison to control groups. The short-term RCTs examined changes in symptoms, with most studies conducted during periods of increased symptom activity and reporting how symptoms evolved in the observed populations across one to three consecutive menstrual cycles. However, evidence is limited regarding long-term functional outcomes that extend beyond these initial few cycles.

---

Evidence for Menorrhagia (Excessive Menstrual Blood Loss)

For excessive menstrual blood loss (menorrhagia), evidence is derived from controlled clinical trials that included premenopausal women. These trials were designed to measure menstrual blood loss volume and associated functional outcomes, often through specific objective measurement methods, and to track related outcomes such as subjective reports of bleeding intensity.

These trials reported measurements of blood volume and symptom patterns in the observed populations across short-to-intermediate study durations, typically covering three to four consecutive menstrual cycles. While research contributes to the broader evidence landscape, evidence quality varies across studies, and certainty remains low in some systematic reviews due to modest sample sizes in the primary trials. Furthermore, limited information is available for long-term outcomes, particularly concerning sustained observations of blood status indicators.

---

Evidence for Acute Pain and Joint Inflammation

Studies have evaluated Mefenamic Acid in two distinct research areas: outcomes related to acute pain and the evaluation of symptoms associated with inflammatory joint conditions (e.g., arthritis). For acute pain, studies primarily use single-dose RCTs in settings like post-dental surgery, where researchers monitored changes in measured pain outcomes over a very short time, usually just a few hours post-dose. The studies focused on outcomes describing episodic or acute changes to assess short-term symptom patterns.

For chronic joint conditions like Osteoarthritis and Rheumatoid Arthritis, evidence was evaluated in controlled studies that focused on outcomes related to physical discomfort, such as measuring changes in joint tenderness and swelling over study periods lasting several weeks to a few months. The studies monitored changes in joint-related pain and tenderness scores over the observation period. A key limitation is that much of this arthritis evidence is derived from older trials, meaning comparative evidence against the full spectrum of newer available treatments is limited.

---

Long-Term Studies and Follow-Up Duration

Studies involving Mefenamic Acid frequently focus on short-term symptom measurement or episodic study protocols, such as those for the menstrual cycle. Therefore, the available research predominantly reflects short-term or intermediate-term observation periods. Long-term outcomes remain insufficiently characterized. Evidence for the durability of any observed response is limited. Studies help show what has been observed so far, but follow-up durations were limited, meaning research provides context but not individual predictions about outcomes after many months of use.

---

Evidence in Specific Patient Groups

Research for Mefenamic Acid primarily draws conclusions from studies conducted on generally healthy adults with the target conditions. Consequently, data for certain groups remain insufficient. For instance, while some studies included adolescents for dysmenorrhea, available data for children remain insufficient. Furthermore, there is limited information available that specifically characterizes the use or responses in older adults or those with multiple co-existing chronic conditions. The research describes findings observed in the studies, and results apply only to the populations studied.

---

What Remains Uncertain in the Research Record

The research evidence, while extensive in areas like dysmenorrhea, indicates that there are still areas of uncertainty or insufficient data. Official reviews often note that the sample sizes were modest in some primary studies, and the evidence quality varies across trials, particularly those concerning heavy menstrual bleeding. There is limited information for long-term outcomes, as most studies explored short-term symptom measurement. Comparative evidence against all modern therapeutic options is also an area where data are still emerging, meaning that the full scope of how Mefenamic Acid performs relative to every alternative remains uncertain. Research provides insight into short-term changes, but does not determine whether an individual will respond similarly.

Common questions about Femina (FAQ)

---

Q: How quickly does Femina typically start working for its intended use?

A: Mefenamic Acid, the active ingredient in Femina, is described in official documents as being rapidly absorbed after it is taken by mouth. Based on pharmacokinetic studies, the highest concentration of the medicine in the blood is typically reached within two to four hours following a single dose. This characteristic aligns with its use for conditions requiring rapid onset of action, as described in official documents.

---

Q: What is the usual duration of a course of treatment with Femina?

A: Regulatory guidelines specify a limited duration for treatment. For managing acute pain, the total course of therapy should not exceed one week. When used for conditions like primary dysmenorrhea (painful menstruation), treatment is generally limited to a period of two to three days per cycle.

---

Q: Are there any long-term effects associated with using Femina?

A: Official warnings indicate that the risks associated with this type of medicine may increase with how long it is used. For example, the documented risk of serious cardiovascular events (such as heart attack or stroke) may increase with the duration of use. Regulatory documents emphasize the principle of using the lowest effective dose for the shortest possible duration, consistent with the drug’s short-term indications.

---

Q: Can Femina interact with common pain relievers like ibuprofen or aspirin?

A: Official regulatory warnings describe potential interactions with other pain relievers. Using Mefenamic Acid alongside other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), such as Ibuprofen, is generally not recommended due to an increased risk of severe stomach and intestinal side effects. Additionally, combining it with Aspirin (used as an anti-platelet agent) may increase the risk of bleeding.

---

Q: What should be done if a person experiences an unexpected side effect from Femina?

A: Official patient guidance describes that symptoms of serious events, such as those related to internal bleeding or cardiovascular issues, should be noted. The regulatory documents also specify that the occurrence of persistent diarrhea or a severe rash is noted as a condition requiring discontinuation of the medicine.

---

Q: Can Femina affect fertility or reproductive health?

A: Regulatory information indicates that NSAIDs like Mefenamic Acid may potentially affect egg release (ovulation) in women. This potential effect is described as being reversible when a person stops using the medication.

---

Q: Does taking Femina cause weight changes?

A: Official warnings note that Mefenamic Acid, like other NSAIDs, has been associated with fluid retention and edema (swelling) in some patients. Fluid retention is a documented side effect, which can result in observed changes in weight.

---

Q: Is Femina a generic medicine, or is it brand-name only?

A: Femina is a common trade name for the active substance Mefenamic Acid. This active ingredient is available for prescription in both brand-name products and its less expensive generic form.

---

Q: Can Femina affect sleep patterns?

A: Official drug documents list drowsiness and fatigue as possible undesirable effects of the medication. Some regulatory sources also note that changes in sleep have been reported as a sign of depression, which is a rare but documented side effect.

---

Q: Is there a maximum time someone can use Femina safely?

A: Official guidelines limit the course of treatment for acute pain and for primary dysmenorrhea to specific, short-term durations. This adherence to short-term protocols aligns with its official indication as a treatment that is not intended for continuous, long-term use.

---

Q: Is it possible to become dependent on Femina?

A: Mefenamic Acid is officially classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). It is not listed as a controlled substance and is not an opioid, which are characteristics that separate it from medications associated with physical dependence.

---

Q: Does alcohol consumption affect how Femina works?

A: Official regulatory information specifically states that consuming alcohol while using Mefenamic Acid significantly increases the risk of stomach bleeding. The combination presents a documented risk regarding gastrointestinal health.

---

Q: How long does Femina stay in the body after the last dose?

A: The elimination half-life of Mefenamic Acid is approximately two hours. The half-life is the time it takes for half of the drug to be eliminated from the body. However, it should be noted that the drug’s metabolites, or breakdown products, may have longer half-lives.

---

Q: Can Femina cause mood changes or depression?

A: Official documentation for Mefenamic Acid lists depression as a rare or uncommon side effect that has been reported. This effect is noted among the range of possible side effects that affect mood.

---

Q: Do I need to have regular blood tests while taking Femina?

A: Regulatory guidance notes that for therapy extending beyond short periods, monitoring through blood work checked periodically may be recommended. This is to monitor for any adverse effects on organs like the liver, which are noted in the official warnings.

---

Q: Does Femina interfere with laboratory test results?

A: Yes, official patient guidance notes that Mefenamic Acid may affect the results of certain lab tests. Therefore, official patient information describes the need to inform all healthcare providers and laboratory personnel that the medication is being taken.

---

Q: Is it necessary to inform a dentist or surgeon about using Femina?

A: Official patient information advises telling all healthcare providers—including doctors, nurses, pharmacists, and dentists—that this drug is being taken. Regulatory sources advise informing all providers, which includes dentists and surgeons, due to the drug’s potential effect on bleeding risk.

---

Q: Are there known interactions between Femina and over-the-counter cold medicines?

A: Many over-the-counter cold medicines contain other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Regulatory documents advise caution against combining Mefenamic Acid with any other NSAIDs because doing so significantly increases the documented risk of serious gastrointestinal events.

Storage and Protection Requirements

Femina (Mefenamic Acid) capsules must be stored at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container and the container must remain tightly closed to protect the contents from excessive moisture and humidity. The product must be stored out of the reach and sight of children as a mandatory safety requirement.

Official Disposal Instructions

Expired or unused capsules should be disposed of by utilizing an authorized drug take-back program or prepaid drug mail-back envelope. If no take-back option is available, the drug must be removed from its container, mixed with an unappealing substance (like dirt or coffee grounds), and placed in a sealed bag for disposal in the household trash. This medicine is not on the FDA flush list, and therefore must not be flushed down the toilet.